ABOUT THIS STUDY
- Age ≥ 18 years
- Patients with advanced or metastatic renal cell carcinoma, histologically confirmed, with at least one radiological response assessment
- Patients who had received Axitinib treatment in second or further line with a PFS ≥9 months or DP (disease progression) at the first tumor assessment.
- For the patients alive at the moment of the inclusion, patients must have a signed informed consent document
- Axitinib received out of the approved indication Patients who do not meet any of the
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New York, New York
- Toronto, Ontario
- Durham, North Carolina